NGM BIOPHARMACEUTICALS INC·4

Mar 6, 5:08 PM ET

Lieu Hsiao D 4

4 · NGM BIOPHARMACEUTICALS INC · Filed Mar 6, 2023

Insider Transaction Report

Form 4
Period: 2023-03-02
Lieu Hsiao
SVP, Chief Medical Officer
Transactions
  • Award

    Common Stock

    2023-03-02+53,00055,605 total
  • Award

    Stock Option (Right to Buy)

    2023-03-02+159,000159,000 total
    Exercise: $4.36Exp: 2033-03-01Common Stock (159,000 underlying)
Footnotes (3)
  • [F1]Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027.
  • [F2]Includes 1,352 shares acquired under the Issuer's Employee Stock Purchase Plan (the "ESPP") on November 15, 2021, 1,252 ESPP shares acquired on May 13, 2022 and 1 ESPP share acquired on November 15, 2022.
  • [F3]The shares subject to the stock option vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION